Tucatinib original research and generic drug price comparison and purchasing advice

Tucatinib (Tucatinib) is an important HER2-targeted therapeutic drug. Currently, its original version has not been officially marketed in China. Therefore, patients cannot purchase the drug through formal channels in China, nor can they enjoy medical insurance reimbursement. This puts certain restrictions on the use of tucatinib in China, and patients need to obtain the drug through overseas channels.

In the European market, the original drug specification of tucatinib is 150mg*84 tablets. Each box sells for about 40,000 yuan, which is relatively high. This is mainly due to the fact that as an innovative drug, its research and development costs and market protection mechanism have led to high prices, which has put greater economic pressure on patients. Although expensive, the clinical efficacy and safety of the original drug are fully guaranteed.

In order to reduce patients’ medication burden, a number of generic drugs of tucatinib have also appeared in overseas markets. For example, a generic drug of 150mg*60 tablets produced by a Lao pharmaceutical factory is priced at more than 2,000 yuan, which is obviously affordable. It is worth noting that the ingredients of these generic drugs are basically the same as those of the original drugs, which can meet the needs of clinical treatment and provide patients with a more economical choice.

Generally speaking, although the original drug of tucatinib has not yet been opened in the domestic market, purchasing generic drugs through overseas formal channels has become the main way for patients to obtain the drug. When choosing, patients should ensure that the purchasing channels are formal, avoid fake and shoddy products, and use medications rationally under the guidance of professional doctors to ensure treatment effects and medication safety.

Reference materials:https://www.drugs.com